Bariatric device and method

Information

  • Patent Grant
  • 11642234
  • Patent Number
    11,642,234
  • Date Filed
    Thursday, August 27, 2020
    3 years ago
  • Date Issued
    Tuesday, May 9, 2023
    a year ago
Abstract
A bariatric device and method of causing at least partial satiety in a recipient includes positioning a body in a recipient, the body having a wall defining a lumen, the wall configured to generally conform to the shape and size of the proximal cardiac portion of the stomach. Force is exerted with the wall on the proximal cardiac portion of the stomach in the absence of food thereby activating receptors located in the proximal cardiac portion of the stomach, thereby influencing a neurohormonal feedback mechanism of the recipient to cause at least partial satiety by augmenting fullness caused by food and simulating fullness in the absence of food.
Description
BACKGROUND OF THE INVENTION

The present invention is directed to a bariatric device and method of causing at least partial satiety in a patient. In particular, the present invention is directed to a bariatric device and a method of causing at least partial satiety in a patient by a noninvasive or minimally invasive technique.


Obesity is a large and increasing problem in the United States and worldwide. In round numbers, from the period encompassing the year 1990 to the period encompassing the year 2000, the prevalence of overweight people (BMI greater than 25) increased from 56 percent of United States adults to 65 percent and the prevalence of obese adults (BMI greater than 30) increased from 23 percent to 30 percent. Likewise, the prevalence of overweight children and adolescents (ages 6-19 years) increased from 11 percent in the period encompassing the year 1990 to 16 percent in the period encompassing the year 2000. The increasing prevalence of overweight among children and adolescents will make the problem even greater when they reach adulthood. The problem is not limited to the United States. Between 10 percent and 20 percent of European men are obese and between 10 percent and 25 percent of European women are obese. Numerous medical conditions are made worse by obesity including Type II diabetes, stroke, gallbladder disease and various forms of cancer. Approximately 500,000 people in North America and Western Europe are estimated to die from obesity-related diseases every year and obesity is estimated to affect more than one billion adults worldwide. Therefore, there is a pressing and unmet need for a solution to the epidemic problem.


Various techniques are known for reducing obesity in patients. Known techniques tend to be based upon restricting food movement and/or nutrient absorption. One example is gastric bypass surgery on the patient, which is highly invasive. The goal of such surgery is to form a pouch from a portion of the stomach to reduce the volume of the space in the stomach receiving food. When the patient ingests food, the pouch is filled which stretches the stomach wall and produces satiety. One difficulty with such procedure is that it requires food to fill the pouch to create satiety. As a result, dietary restrictions are required for effective operation of the pouch. Such restrictions include withholding of liquids during meals to avoid washing the food from the pouch. Also, liquids with substantial calories tend to pass through the pouch without creating substantial satiety. Moreover, the opening from the pouch tends to become enlarged over time, thus allowing more food to pass while achieving reduced satiety. Thus, patients undergoing such surgical techniques often experience gradual weight gain over time.


Alternative weight loss devices and methods have been proposed. However, such devices and methods may be difficult to place in the patient, have questionable efficacy, and may cause undesirable side effects.


SUMMARY OF THE INVENTION

The present invention utilizes a new principle of implied satiation. The present invention provides a bariatric device and method of causing satiety in a patient that augments the natural response of the body. This may be accomplished using a non-invasive or minimally invasive procedure with a device that may be removable or absorbable. Moreover, satiety may be caused in a manner that does not interfere with other body functions, such as operation of normal reflux mechanism, bile ducts, taking of medications, and the like. The implied satiation technique of the present invention does not rely on either the restrictive or malabsorptive techniques of the prior art.


A bariatric device, according to an aspect of the invention, includes a body having a wall defining a lumen. The wall is configured to generally conform to the shape and size of the proximal cardiac portion of the stomach and to exert pressure on the proximal cardiac portion of the stomach in the absence of food, thereby influencing a neurohormonal feedback mechanism of the patient to cause at least partial satiety by augmenting fullness caused by food and simulating fullness in the absence of food. The lumen is substantially unrestricted. At least one fixation mechanism resists distal migration of the body.


The wall may be made from a self-extendable silicone-coated material. The wall may be flared to thereby conform to the cardiac notch of the proximal cardiac portion of the stomach. The body may be generally frusto-conical in shape. The wall may exert a generally consistent radial pressure on the proximal cardiac portion of the stomach. The wall may be at least partially absorbable.


The fixation system may include barbs, V-shaped appendages, metallic anchors extending radially from said body, staples and/or sutures. The wall may be compressible for deployment through the esophagus. The wall may be removable.


A method of causing at least partial satiety in a recipient, according to an aspect of the invention, includes positioning a body at a proximal cardiac portion of the stomach and fixing the body to the recipient to resist migration of the body. The body has a wall defining a lumen and is configured to the size and shape of the proximal cardiac portion of the stomach. The lumen is substantially unrestricted. Pressure is exerted with the wall on the proximal cardiac portion of the stomach in the absence of food, thereby influencing a neurohormonal feedback mechanism of the patient to cause at least partial satiety by augmenting fullness caused by food and simulating fullness in the absence of food.


Anti-nausea medication may be administered to the recipient at least during initial deployment of said body. Nutritional supplements may be administered to the recipient. The body may be generally frusto-conical in shape. A generally consistent radial pressure may be exerted with the wall to the proximal cardiac portion of the stomach. The wall may be at least partially absorbable.


The fixation system may include barbs, V-shaped appendages, metallic anchors extending radially from said body, staples and/or sutures. The wall may be compressed and the body deployed through a recipient's esophagus. The body may be removed after the recipient has experienced sufficient weight loss.


Thus, it can be seen that embodiments of the present invention provide an implied satietor and implied satiation method that does not require food to generate the satiety through the neurohormonal mechanism of the body. This advantageously produces at least partial satiety in the patient in the absence of food, as well as augmenting fullness caused by food during the ingestion of the food. Moreover, because satiety is not caused by food, the patient would not necessarily need to be subject to dietary restrictions, such as withholding of liquids during meals or withholding of liquids having substantial calories.


Moreover, in contrast to surgical procedures, embodiments of the present invention provide a bariatric device and method of causing at least partial satiety that is minimally invasive and which avoids many of the potential side effects of gastric bypass surgery and other surgical procedures, such as adjustable gastric banding, and the like. Also, because of the placement of the device, there is no interference with operation of gastric functions, such as with the bile ducts, and the like. Further, as previously noted, the bariatric device can be adapted to allow the gastro-esophageal junction to function normally without any significant interference or impediment. Also, embodiments of the invention provide a bariatric device and method of inducing at least partial satiety in the patient that does not operate on the basis of causing flu-like symptoms in the patient in a thwarted effort to attempt to induce the patient to eat less, such as may occur by the placement of devices in the patient's duodenum, or the like.


Additionally, in contrast to pouches formed in gastric bypass surgery, embodiments of the present invention do not include a discharge opening that is subject to enlargement with the passage of time, thereby eliminating at least one source of gradual weight gain in patients undergoing gastric bypass surgery.


Moreover, because it is a non-invasive or minimally invasive procedure, embodiments of the present invention may be applied not only to morbidly obese patients, but also to obese patients, overweight patients, adolescents, and potentially even children.


Thus, it is seen that the present invention is embodied in a bariatric device and method including a body having an expandable wall, which evokes normal neurohormonal responses associated with fullness or satiety. The body wall does so by acting on one or more portions of the distal esophagus and/or the cardia of the patient. The normal filling sensation of the stomach is augmented and amplified. Further, it has been found that the body appears to have a “satiety continuum” where a person transitions from hungry, which is on one end of the continuum or spectrum where there is a lack of satiety, to lacking hunger or being satisfied after eating and to being full with continued consumption. If the person continues to eat to the point of overeating, the person then becomes nauseous, which represents the other end of the continuum. As the pressure applied to the distal esophagus and/or the cardia of a patient is increased, the further along the patient will be on this “continuum” or spectrum. Ideally, then for an extremely overweight person, the bariatric device of the present invention may be best used if sufficient pressure is applied so that the patient is on the nausea end of the spectrum or just below at a “sub-nausea” point.


These and other objects, advantages and features of this invention will become apparent upon review of the following specification in conjunction with the drawings.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a diagram of a bariatric device positioned at the abdominal portion of the esophagus, the esophageal-gastric junction and the proximal cardiac portion of the stomach of the patient;



FIG. 2 is a bottom view of the bariatric device in FIG. 1;



FIG. 3 is a perspective view of an alternative embodiment of the bariatric device in FIG. 1;



FIG. 4 is the same view as FIG. 3 of another alternative embodiment;



FIG. 5 is the same view as FIG. 4 illustrating an alternative control technique;



FIG. 6 is the same view as FIG. 2 of yet another alternative embodiment;



FIG. 7 is the same view as FIG. 6 illustrating adjustment of restriction;



FIG. 8 is the same view as FIG. 2 of yet another alternative embodiment;



FIG. 9 is the same view as FIG. 2 of yet another alternative embodiment;



FIG. 10 is the same view as FIG. 1 of yet another alternative embodiment;



FIG. 11 is the same view as FIG. 1 of yet another alternative embodiment;



FIG. 12 is the same view as FIG. 2 of yet another alternative embodiment;



FIG. 13 is the same view as FIG. 2 of yet another alternative embodiment;



FIG. 14 is the same view as FIG. 2 of yet another alternative embodiment;



FIG. 14A is a perspective view of an alternate embodiment of the bariatric device of FIG. 1; and



FIG. 15 is a block diagram of a technique for selecting the level of pressure exerted by the body wall.





DESCRIPTION OF THE PREFERRED EMBODIMENT

Referring now specifically to the drawings, and the illustrative embodiments depicted therein, a bariatric device, or implied satietor, 15, which causes satiety by acting on the abdominal portion of the esophagus, and/or the esophageal-gastric junction and/or the proximal cardiac portion of the stomach, is illustrated in FIG. 1 being positioned in the patient. Device 15 includes a body 16 having an expandable wall 17 thereby defining a transverse passage, or lumen 18 through the body. Body 16 is designed to conform to the shape and size of the abdominal portion of the esophagus, the esophageal-gastric junction and/or the proximal cardiac portion, or cardia, of the patient's stomach. The present invention is embodied in various bariatric devices. The devices may be removable, absorbable and/or permanent. The devices may be manufactured from a synthetic or a bioprosthetic material. While the invention is illustrated with a mesh wall, other configurations are possible, such as coil configurations, and the like. Bariatric device 15 may be positioned utilizing various techniques, such as endoscopic placement with fluoroscopic assist.


Wall 17 is configured to exert an outward pressure, typically a generally radial outward pressure, at the abdominal portion of the esophagus, the esophageal-gastric junction and/or the cardia of the patient. This may be accomplished, for example, by configuring the wall to have a proximal portion 17a to create an interference fit with the abdominal portion of the esophagus and/or a central portion 17b configured to create an interference fit with the esophageal-gastric junction and/or a distal portion 17c configured to create an interference fit with the patient's cardia. The pressure exerted by wall portions 17a, 17b and/or 17c influences the neurohormonal feedback mechanism present at the esophagus and/or stomach to cause at least partial satiety. As will be discussed in more detail below, the pressure exerted by the extendable wall may be fixed or adjustable. The force that influences the neurohormonal feedback mechanism present at the abdominal portion of the esophagus, the esophageal-gastric junction and/or the cardiac portion of the stomach is intended to be relatively consistent over as large an area as reasonably possible. The force exerted by the wall of the bariatric device is believed to activate stretch receptors located in the abdominal portion of the esophagus, the esophageal junction and/or the cardia. In contrast to prior proposed devices, which require that the patient ingest food in order to influence neurohormonal feedback mechanisms, bariatric device 15 simulates fullness in the absence of food. It also augments fullness caused by food.


This interference fit may be created by a self-extendable, or self-expanding, wall. Alternatively, it may be created by an extendable wall, such as a balloon-extendable wall. The extended wall diameter is chosen so that it is somewhat oversized compared to the diameter of the conduit in which it is positioned, namely, the abdominal portion of the esophagus, the esophageal-gastric junction and/or the cardia. A self-extendable wall may be, by way of example, formed from a material, such as metal, fibers or fibrous materials, including carbon fibers, and may be a wall made from a self-extendable silicone-coated material. For example, the wall may be formed from a metal sheet, such as a Nitinol sheet, formed for example, by laser cutting, or from a coil or lattice structure formed from a metal or carbon fiber, which may be encapsulated or embedded in an insert polymer, such as silicone or the like. Alternatively, the wall may be extended by a balloon or fluid extendable reservoir expanding the wall outwardly, including generally radially outwardly, to a position firmly against the wall of the conduit in which the body is inserted. This inflation may be accomplished endoscopically with a blunt needle or with a control as will be discussed in more detail below.


As can be seen in FIG. 1, wall 17 is longitudinally non-symmetrical with respect to the central longitudinal axis “L” defined by the direction of movement of the food along the patient's esophagus and stomach. In particular, as one moves along axis L, the cross-sectional configuration of wall 17 varies proximally to distally. For example, wall portions 17a and 17b are generally cylindrical in shape and wall portion 17c is frusto-conical in shape, flaring outwardly from a distal end of wall portion 17b. Wall portion 17c is angled to conform to the cardiac notch. Wall 17 may also be radially non-symmetrical with respect to this longitudinal axis “L”. In particular, certain portions of wall 17 are at a greater radial distance from axis L than portions of the wall at a different location around axis L. For example, wall portion 17c is enlarged at 19 to extend to more of the fundus of the cardia, such as the angle of His. This enlarged portion 19 makes wall 17 radially nonsymmetrical with respect to axis “L”.


The narrow portion of lumen 18, which generally is the portion in the patient's esophagus, may have a length that is no longer required to provide enough force to produce satiety. In the illustrative embodiment, the narrow portion of lumen 18 is less than 9 cm in length. In certain embodiments, the narrow portion of lumen 18 is in the range of between 6 cm and 7 cm in length. This reduces the tendency of food to get caught in the lumen as well as any interference with peristalsis of the esophagus while producing force over a sufficient surface area to produce satiety.


In the embodiment illustrated in FIG. 1, bariatric device 15, and corresponding method of causing satiety in a patient, includes providing at least a portion 20 of middle wall portion 17b that does not exert a substantial pressure or force. Such portion may be made from a flaccid material, such as a non-self-expandable material, or may be formed from a plurality of discrete wall portions that simply connect the proximal portion 17a to the distal portion 17c, as more fully described in reference to FIG. 14A below. These discrete wall portions may be interconnected to form a mesh or may be unconnected from each other to simply act as connectors between the proximal portion 17a and the distal portion 17c. The device would be positioned such that the non-self expanding portion 20 covers the gastro-esophageal sphincter. This would allow the anti-reflux mechanism of the gastro-esophageal junction to operate generally normally because the wall of portion 20 would not exert any significant pressure on the sphincter. This embodiment allows the patient to belch, vomit, and the like, while resisting reflux. In bariatric device 15, proximal wall portion 17a is self-expandable and is generally cylindrical in shape to conform to the shape and size of the abdominal portion of the esophagus and distal wall portion 17c is self-expandable and is generally frusto-conically in shape to conform to the shape and size of the proximal cardiac portion of the stomach.


Bariatric device 15 may include a fixation system 21, which is capable of resisting distal migration of the device. Fixation system 21 may include a series of anchors 22 illustrated as a series of V-shaped downwardly directed appendages from wall 17. Alternatively, the anchors may be in the shape of downwardly directed barbs or hooks, metallic anchors extending radially from said body, or the like. Such arrangement provides fixation against migration, typically distal migration, while allowing the device to be easily removed from the patient because the anchors may be configured to provide less resistance to proximal movement. In the embodiment illustrated in FIG. 1, the anchors are positioned at or near the esophageal-gastric junction, such as proximally at distal portion 17c of the wall. This positioning of the anchor takes advantage of the fact that the esophageal gastric junction is thicker and, therefore, stronger at this location.


A bariatric device 115 includes a wall 117 having a proximal wall portion 117a that applies outward pressure, such as generally radially outward pressure, to the abdominal portion of the esophagus, a distal portion 117c that applies outward pressure, such as generally radially outward pressure, to the proximal cardiac portion of the stomach, and a middle portion 117b that is positioned at the esophageal-gastric junction (FIG. 2). As with bariatric device 15, in bariatric device 115 the central portion 117b is made from a non-expandable material, such as a flaccid material 120. Also, distal portion 117c includes an enlarged portion 119 that extends to more of the function of the cardia, such as the angle of His. Flaccid material 120 includes openings 123 that allow ingrowth of material. Openings 123 define at least in part a fixation system 121. Fixation system 121 may include a secondary, or temporary, means for anchoring bariatric device 115 while allowing tissue to ingrowth through openings 123. Such secondary fixation system may include stitches, staples, or the like. Openings 123 may be sized appropriately to accept such stitches or staples. The sutures could be dissolvable or non-dissolvable. Openings 123 may be as few as, for example, five openings in the flaccid material portion 120. Alternatively, they may be a lattice of small holes that allow tissue ingrowth. The use of tissue ingrowth utilizes the body's reaction to the bariatric device 115 in order to assist in fixing the device against distal migration. Further, the tissue ingrowth, which results from the mucosa essentially incorporating the device into the anatomy of the patient, provides resistance to infection. This ingrowth can be in a portion of the device body or through the entire device body. While some irritation of the mucosa may occur when bariatric device 115 is removed, any such irritation should be relatively minor and readily healed. As with all fixation systems described herein, fixation system 121 may be used in combination with other fixation systems, such as fixation system 21, or the like. Alternately, the tissue ingrowth may be used to promote permanence—in other words to incorporate the device into the body of the patient.


An alternative bariatric device 215 includes a body 216 having an expandable wall 217 (FIGS. 4 and 5). Expandable wall 217 defines an internal chamber 24 throughout at least a portion of the proximal portion 217a, middle portion 217b and distal portion 217c of wall 217. Chamber 24 may be a single unitary chamber that extends the length of wall 217 or may be a series of separate chambers that are either interconnected or separated from each other. For example, a chamber may be positioned around proximal portion 217a of wall 217 that is sized and shaped to be positioned at the patient's abdominal esophagus and a chamber may be positioned at distal portion 217c that is sized and shaped to be positioned at the patient's cardia while no chamber is present at all or a portion of 217b that is configured in size to be at the esophageal-gastric junction of the patient. In this manner, wall 217 would not be substantially expandable at the gastro-esophageal sphincter, thereby reducing interference with normal operation of such sphincter, as previously discussed.


As can be seen in FIG. 4, a port 25 may be provided to chamber 24 in order to allow access by a needle 26 connected with a device 27 that is endoscopically inserted in the patient and used to either add fluid to or remove fluid from chamber 24. In this manner, the amount of force exerted by wall 217 may be varied or adjusted. In this manner, for example, a greater amount of force may be applied to a morbidly obese patient, such as one that is more than 40 pounds overweight, while a lower amount of pressure may be applied to patients that are overweight or mildly obese, such as those that are 30 to 40 pounds overweight, for example. Bariatric device 25 is illustrated with a fixation system in the form of anchors 22, although other fixation systems previously described may be utilized. Additionally, distal portion 217c may be radially symmetrical with respect to the longitudinal axis “L” of the device or may be non-symmetrical by including the enlarged portion of distal wall portion 217c as previously described.


As illustrated in FIG. 5, reservoir 24 of bariatric device 215 may, alternatively, be connected with a fluid reservoir 28 positioned within the patient and including a control 29 that is configured to selectively transfer between fluid reservoir 24 in the bariatric device and fluid reservoir 28 in the patient. In this manner, control 29 may control the amount of fluid in fluid chamber 24, thereby adjusting the amount of force exerted by the wall 217 of the device on the conduit in which it is positioned. An optional patient operable control 31 may be provided and interconnected with internal control 29, such as by a radio-frequency link 32, in order to allow a patient or medical attendant to modify the amount of pressure exerted by wall 217.


Control 29 may provide for a temporal adjustment of the amount of pressure exerted by bariatric device 215 on the patient's distal esophagus and/or proximal stomach. By way of example, control 29 may include an algorithm that causes fluid to be transferred from fluid reservoir 30 to fluid chamber 24 of the device 215 in order to increase the amount of pressure, typically radial pressure, exerted by wall 217 during general waking hours of the patient when satiety is desired. Control 29 can further be programmed to transfer fluid from reservoir 24 to reservoir 30 during periods of time when the patient is expected to be sleeping and satiety is not required. Patient control 31 may, alternatively, allow manual adjustment of the amount of force exerted by wall 214 of device 215. For example, when the patient retires at night, the patient may operate user control 31 in order to instruct control 29 to transfer fluid from chamber 24 to fluid reservoir 30, thereby reducing pressure exerted by wall 217. When the patient awakes, the patient may then utilize user control 31 in order to cause control 29 to increase the amount of pressure exerted by wall 217. This temporal control of the amount of force exerted by wall 217 should overcome any potential tachy phylaxis that may result in the diminishing response of the neurohormonal system of the patient to the force exerted by wall 217. Alternatively, the temporal control may be utilized, where appropriate, to adjust the amount of pressure with respect to eating times of the patient, or the like. Control 29 may, alternatively, monitor certain hormonal levels of the patient in order to determine when the patient is expected to eat a meal and may even be a self-learning control system in order to learn the variations in the patient's hormonal levels.


An alternative bariatric device 315 may further include a restriction component 33 restricting discharge of food from lumen 18 (FIG. 6). Restriction component 33 may be in the form of a chamber 34 extending within the lumen of body 316. In the illustrative embodiment, restriction component 33 is adjacent to distal portion 317c of wall 317, but could be at other locations along wall 317. Chamber 34 may be increased or decreased in volume utilizing various techniques, such as by adding or withdrawing a fluid, such as a gas or a liquid, via a blunt needle 26 (FIG. 7). Other known devices, such as an external electronic device that communicates with a control (not shown) and a pump/fluid reservoir within the patient, may be used to adjust the size of restriction component 33. With such configuration, the external control may actuate the pump through the internal control in order to increase or decrease the size of chamber 24. Alternatively, the internal control may be programmed to carry out the adjustment. Chamber 28 restricts the cross-section of lumen 18. Such restriction resists egress from lumen 18 of walls 16 and thereby resists the continued ingestion of food past device 315. This may be useful in patients who tend to continue to eat past satiety.



FIG. 8 illustrates an alternative bariatric device 415 having a body 416 with a restriction component 133 in the form of an inflatable reservoir or chamber 134, which surrounds the distal portion 418a of the lumen 418. Reservoir 134 provides an adjustable restriction wherein, as additional fluid is added to chamber 134, the increase in the volume of the chamber restricts the diameter of lumen 418 thereby adjusting the ability to resist egress from the lumen of bariatric device 415 thereby providing a variable restriction to ingestion of food. Chamber 134 may also be capable of increasing the external diameter of the device wall 417c thereby placing additional pressure on stretch receptors at the cardia of the patient's stomach.


An alternative bariatric device 515 may include a body 516 having a wall 517 including an anti-reflux component 35 (FIG. 9). Anti-reflux component 35 may be in the form of a one-way valve in order to resist reflux from the stomach to the esophagus. As best seen in FIG. 9, anti-reflux component 35 may be in the form of a tubular extension of lumen 518 that expands to allow distal movement of food but collapses to reduce reflux.


An alternative bariatric device 615 includes a body 616 having a wall 617 that is self-expandable at a proximal portion 617a, a middle portion 617b and a distal portion 617c, the latter being configured to the cardiac notch of the patient (FIG. 10). Bariatric device 615 includes a fixation system 21, such as a series of anchors 22, at the esophageal-gastric junction of the patient. The entire surface of wall 617 is made of a self-expanding material.


An alternative bariatric device 715 illustrated in FIG. 11 has a body 716 in which egress from the lumen 718 is from a discharge portion 40 of the device located at or near the patient's intestines. This provides additional weight loss by substantially bypassing the patient's stomach and discharging to the intestines. Device 715 may include a series of perforations 36 at discharge portion 40 in order to distribute the egress from lumen 718 along the small intestine of the patient. Use of bariatric device 715 may require dietary restrictions to avoid food collection in the elongated lumen.


Anchors may be positioned at various locations along the exterior of the wall of the device. For an example, an alternative bariatric device 815 is illustrated in FIG. 12 with a body 816 having a wall 817 having anchors, such as V-shaped appendages, barbs, or hooks distributed along the outer wall of the body. The fixation system may also be in the form of a balloon-expandable wall 817c defining a chamber 37 that applies sufficient pressure on the conduit in which the device is located in order to resist distal migration of the device. The balloon can extend the device wall to produce fixation and can be deflated in order to allow the device to be removed. FIG. 13 illustrates an alternative bariatric device 815′ having a body 816 with a wall 817 defining a lumen 818 without a chamber. Other fixation systems may be apparent to the skilled artisan, such as stitching, stapling, and the like.


An alternative bariatric device 915 illustrated in FIG. 14 includes a body 916 having a wall 917 that is positioned virtually entirely within the patient's stomach. Wall 917 is of a size and shape to conform to the cardiac portion of the stomach, cardia, and is configured to exert pressure, typically radial pressure, on the cardia. Device 915 includes a fixation system 922 that engages the cardia or the esophageal-gastric junction.


As noted above, the non-self-expanding portion of bariatric device of the present invention may be formed from discrete wall portions. Referring to FIG. 14A, device 1015 is of similar construction to device 15 and includes a body 1016 having an expandable wall 1017, which defines a lumen 1018. Wall 1017 is similar to wall 17 and includes a proximal portion 1017a to exert pressure on the abdominal portion of the esophagus and a distal portion 1017c that is configured to exert pressure on the cardia. For further details of portions 1017a and 1017c reference is made to the previous embodiments.


In the illustrated embodiment, the central portion 1017b of the body 1016 is formed from discrete wall portions 1020, which connect the proximal and distal portions 1017a, 1017c of wall 1017 together. Wall portions 1020 may act as tension members between the distal portion and the proximal portion and may further act as compression members to maintain the distal and proximal portions at a desired spacing, but which do not exert any significant outward or radial pressure on the gastro-esophageal junction. Wall portions 1020 may be generally equal in size and evenly spaced around the perimeter of body 1016 or may be unevenly spaced and, further, may have different widths and lengths. For example, the lengths of the wall portions may fall in a range of 0.75 cm to 1.5 cm. The number of wall portions may vary, with the illustrated embodiment depicting four wall portions that are generally evenly spaced around the perimeter of body 1016.


As noted above, wall portions 1020 optionally form a non-self-expanding portion of wall 1017 and align with the gastro-esophageal junction to allow the junction to function normally. The spaces between the wall portions 1020 may comprise holes or openings or may be filled by a flexible membrane or flaccid material.


In addition, wall portions 1020 may provide fixation points, for example, for sutures to secure device 1015 at or near the gastro-esophageal junction in which case the material forming wall portions 1020 may formed from a relatively stiff material, such as fibers or fibrous material, for example, embedded in silicone, for example.


Further, the upper open end or entrance of body 1016 may be flared outwardly to bear or seal against the esophageal wall to essentially close off the space or gap between device 1015 and the esophagus.


Various delivery systems may be utilized to deliver any of the bariatric devices 15-1015 to the patient. Such a delivery system may include a tube device (not shown) into which the bariatric device is compressed. The tube device may be a stiff or flexible tube and be sized and shaped to easily fit within the patient's esophagus. Such a delivery system includes a deployment mechanism (not shown) to retract the bariatric device from the tube. As the bariatric device is removed from the tube, it assumes its expanded form. If a self-expanding wall is utilized, the bariatric device will assert pressure, such as a generally radial pressure, on the distal esophagus and/or the cardia of the patient when removed from the tube. If an expandable wall is utilized, such as a bladder, the bladder is inflated in order to exert pressure. Various markers, such as fluorescent markers, may be applied to the wall of the bariatric device in order to allow for fluoroscopic assist in the placement of the device.


A method 50 may be provided for monitoring and, if desired, adjusting the amount of satiety produced by the bariatric device and method (FIG. 15). In method 50, a bariatric device 15-1015 is inserted in the patient at 52 and a level of pressure, such as generally radial pressure, is applied by the body wall of the device. The level of satiety is monitored, such as by monitoring the patient's hypothalamus at 54, such as with a Positron Emission Tomography (P.E.T.) scan. The P.E.T. scan produces a visual image of the hypothalamus that changes colors with the amount of activity of the hypothalamus. By observing the color of the hypothalamus through the P.E.T. scan, a determination is made at 56 whether an appropriate level of satiety is obtained. If it is, then the procedure is done at 58.


If it is determined at 56 that an appropriate level of satiety is not being obtained, the process returns to 52 where a different level of pressure may be adjusted by the body. The adjustment of pressure may be in the form of adding or subtracting fluid from a bariatric device having an expandable wall by the use of a chamber 24. Alternatively, the adjustment of the pressure may be in the form of deploying a different size or characteristic device, which is self-expandable and applies a different force to the patient through the self-expandable wall. The amount of satiety may be different for different patients. For example, a patient who is overweight may require a particular level of pressure, whereas a more obese, such as a morbidly obese, patient may require a higher level of satiety. Likewise, a child or an adolescent may require different levels of pressure. The ability to obtain immediate feedback on satiety strength allows the efficacy of the system to be established at deployment rather than monitoring the patient for weight loss and adjusting it after the patient has lost either too much or too little weight.


Alternately, the amount of satiety can be gauged by where the patient falls on the satiety continuum—that is whether they are hungry, satisfied, full or even nauseous. For a morbidly obese person, it may be desirable to apply sufficient pressure so that the patient is nauseous and then optionally reduced slightly so that the patient just below being nauseated or at a sub-nauseous level. This may be particularly useful when a remote control is being used in combination with an adjustable device where the patient may themselves adjust the level of pressure to maintain their desired or a prescribed level of satiety.


Any of the bariatric devices 15-1015 may be used as part of a multi-disciplinary comprehensive program. This may include the adjustment of medications as the patient experiences weight loss. For example, for patients taking diabetic medications, less insulin may be required as a patient loses weight. Also, blood pressure medications and other medications may be adjusted as the patient loses weight.


Because of the ability of the bariatric device 15-1015 to cause satiety, it is possible, in certain patients, that the patient will require nutritional supplements, such as protein liquids, in order to ensure adequate nutritional needs, such as protein intake. Also, anti-nausea medications may be given to the patient, especially at the beginning of the placement. This is because a bariatric device, according to the invention, may cause nausea at the beginning of the placement.


In order to reduce the likelihood of food getting caught in the lumen and in order to minimize interference with natural peristalsis in the esophagus, the length of the lumen is generally kept below 9 cm. In most embodiments, the length of the lumen is in the range of approximately 6 cm to approximately 7 cm. Widened portions of the body, such as distal portions 17c-1017c, are not considered part of the lumen for determining the length of the lumen. The expandable wall, whether self-expanding or balloon-expandable, should provide consistent pressure over as large an area as possible in order to induce adequate satiety, consistent with an effort to keep the lumen as short as possible.


Thus, it is seen that the present invention introduces a new category of weight loss techniques: implied satiation. The invention advantageously utilizes stretch receptors, such as those located at the abdominal portion of the esophagus and/or esophageal-gastric junction and/or the cardiac portion of the stomach of the patient to cause satiety. In contrast to gastric bypass surgery and adjustable gastric bands, the present invention does not require surgical intervention. In that regard, the present invention provides a non-invasive or minimally invasive alternative. However, the invention may be utilized in combination with known restrictive and/or malabsorptive techniques, such as gastric bypass surgery and adjustable gastric bands to further help the patient lose weight. Advantageously, the present invention may be applied to patients who are contraindicated for surgery, such as those with mildly high obesity and for those at risk for surgery. Also, the invention may be used to achieve sufficient weight loss in morbidly obese patients to stabilize the patient for gastric bypass surgery. Moreover, the present invention may be properly sized for use with children and adolescence. Thus, the present invention provides a non-intrusive or minimally intrusive technique for addressing the increasing epidemic of obesity in adolescents and children, as well as adults.


The present invention also comprehends an implied satietor that is capable of exerting pressure at the patient's abdominal portion of the esophagus, esophageal-gastric junction and/or cardia, such as by suitable dimensioning of a self-expanding wall or by a mechanism for expanding the wall outwardly. Examples of such a mechanism may be a bladder mechanism whereby the wall could exert varying pressures. The present invention also has the capability of assisting in reducing esophageal leakage. This may further enhance the use of the invention in combination with other techniques, such as gastric bypass surgery, esophageal tumors, and the like. In addition to influencing the neurohormonal feedback mechanism present at the abdominal portion of the esophagus, the present invention is capable of resisting egress from the lumen of the satiety device. This provides additional benefit to certain patients by resisting their ability to ingest food beyond satiety. Because the device may be inserted endoscopically with fluoroscopic assist, the device may be suitably and accurately positioned at the desired location within the patient's esophagus, esophageal-gastric junction and/or cardia and adjustments made to the satiety device as required. Moreover, the device may be subsequently removed from the patient if indicated. The use of various fixation systems allow the device to be positioned at or near the abdominal portion of the esophagus, the esophageal-gastric junction and/or the cardia while resisting distal migration of the device. Moreover, the use of such fixation system may allow for the satiety device to be readily removed from the patient.


Evidence of the viability of the invention can be seen by its principle having been reduced to practice and found to cause weight loss in patients. The patients, who ranged from non-obese to morbidly obese, lost weight, generally over a one or two week period during which the device was in place. The patients experienced some initial nausea. They reported satiety throughout placement of the device. When the device was no longer present, the patients regained hunger.


Changes and modifications in the specifically described embodiments can be carried out without departing from the principles of the invention, which is intended to be limited only by the scope of the appended claims, as interpreted according to the principles of patent law including the doctrine of equivalents.

Claims
  • 1. An intraluminal device adapted to be deployed in a recipient having a gastro-intestinal (GI) tract comprising an esophagus, a stomach with a cardiac portion and an esophageal gastric (EG) junction having a sphincter between the esophagus and the cardiac portion of the stomach, the intraluminal device comprising: a body having a wall defining a lumen, said wall having at least one selected from (i) an esophageal wall portion configured to generally conform to the shape and size of the abdominal portion of the esophagus (ii) an EG wall portion that is sized to generally conform to the size and shape of the EG junction and (iii) a cardiac wall portion that is sized to generally conform to the size and shape of the cardiac portion of the stomach; andsaid at least one selected from said esophageal wall portion, said EG wall portion and said cardiac wall portion adapted to exert force in the absence of food to a portion of the GI tract of the recipient to thereby influence a neurohormonal feedback mechanism of the recipient to cause at least partial satiety by augmenting fullness caused by food and simulating fullness in the absence of food.
  • 2. The intraluminal device as claimed in claim 1 wherein said wall has said cardiac wall portion, wherein said cardiac wall portion is adapted to exert force at least on the cardiac portion of the stomach.
  • 3. The intraluminal device as claimed in claim 2 wherein said wall has said esophageal wall portion and said EG wall portion and wherein said EG wall portion is adapted to not exert a substantial force at the EG junction of the recipient in order to allow the sphincter of the EG junction of the recipient to operate generally normally.
  • 4. The intraluminal device as claimed in claim 3 wherein said EG wall portion comprises a plurality of spaced apart tension members between the esophageal wall portion and the cardiac wall portion.
  • 5. The intraluminal device as claimed in claim 1 wherein said wall is adapted to exert a generally constant force on the portion of the GI tract.
  • 6. The intraluminal device as claimed in claim 1 wherein said wall is adapted to exert an adjustable force on the portion of the GI tract.
  • 7. The intraluminal device as claimed in claim 6 including a control, said control is adapted to controlling an amount of force exerted by said wall on the portion of the GI tract.
  • 8. The intraluminal device as claimed in claim 7 wherein said control is adapted to temporally adjust an amount of force exerted by said wall on the portion of the GI tract.
  • 9. The intraluminal device as claimed in claim 1 including a fixation system that is adapted to resist distal migration of said body.
  • 10. The intraluminal device as claimed in claim 9 wherein said fixation system includes a tissue ingrowth portion of said body that is adapted to facilitate tissue ingrowth.
  • 11. The intraluminal device as claimed in claim 1 wherein said wall is made at least in part of an absorbable material.
  • 12. A method of causing at least partial satiety in a recipient having a gastro-intestinal (GI) tract comprising an esophagus, a stomach with a cardiac portion and a esophageal gastric (EG) junction having a sphincter between the esophagus and the cardiac portion of the stomach, the method comprising: positioning a body having a wall defining a lumen in a portion of the GI tract of the recipient, said wall having at least one selected from (i) an esophageal wall portion configured to generally conform to the shape and size of the abdominal portion of the esophagus, (ii) an EG wall portion that is sized to generally conform to the size and shape of the EG junction and (iii) a cardiac wall portion that is sized to generally conform to the size and shape of the cardiac portion of the stomach;including positioning the wall in at least one selected from (i) the esophagus (ii) the EG junction and (iii) the cardiac portion of the stomach of the recipient; andexerting force in the absence of food to the portion of the GI tract of the recipient with said wall to thereby influence a neurohormonal feedback mechanism of the recipient to cause at least partial satiety by augmenting fullness caused by food and simulating fullness in the absence of food.
  • 13. The method as claimed in claim 12 wherein said wall has said cardiac wall portion and wherein said exerting comprises exerting force with said cardiac wall portion at least on the cardiac portion of the stomach.
  • 14. The method as claimed in claim 13 wherein said wall has said esophageal wall portion and said EG wall portion and wherein said EG wall portion does not exert a substantial force on the EG junction of the recipient in order to allow the sphincter of the EG junction of the recipient to operate generally normally.
  • 15. The method as claimed in claim 14 wherein said EG wall portion comprises a plurality of spaced apart tension members between the esophageal wall portion and the cardiac wall portion.
  • 16. The method as claimed in claim 12 including exerting generally constant force with said wall on the portion of the GI tract.
  • 17. The method as claimed in claim 12 including exerting an adjustable force with said wall on the portion of the GI tract.
  • 18. The method as claimed in claim 17 including temporally adjusting an amount of force exerted by said wall on the portion of the GI tract.
  • 19. The method as claimed in claim 12 including fixing said wall within the portion of the GI tract with a fixation system.
  • 20. The method as claimed in claim 19 wherein said fixation system includes a tissue ingrowth portion of said body and wherein said fixing includes facilitating tissue ingrowth with said tissue ingrowth portion.
  • 21. The method as claimed in claim 12 wherein said wall is made at least in part of an absorbable material.
  • 22. The method as claimed in claim 12 wherein said positioning comprises endoscopic positioning.
CROSS REFERENCE TO RELATED APPLICATIONS

The present invention is a continuation of prior application Ser. No. 15/805,495, filed Nov. 7, 2017, which is a continuation of application Ser. No. 15/211,034 filed Jul. 15, 2016, now U.S. Pat. No. 9,839,545, which is a continuation of U.S. patent application Ser. No. 14/920,403, filed on Oct. 22, 2015, now U.S. Pat. No. 9,414,948, which is a continuation of U.S. patent application Ser. No. 14/314,444, filed on Jun. 25, 2014, now U.S. Pat. No. 9,198,789, which is a continuation of U.S. patent application Ser. No. 14/142,131, filed on Dec. 27, 2013, now U.S. Pat. No. 8,801,599, which is a continuation of U.S. patent application Ser. No. 13/331,425 filed on Dec. 20, 2011, now U.S. Pat. No. 8,672,831, which is a continuation of U.S. patent application Ser. No. 12/915,952, filed on Oct. 29, 2010, now U.S. Pat. No. 8,100,931, which is a continuation of U.S. patent application Ser. No. 11/463,192, filed on Aug. 8, 2006, now U.S. Pat. No. 7,846,174, which is continuation-in-part application of International Application No. PCT/US2005/036991, filed on Oct. 13, 2005, entitled BARIATRIC DEVICE AND METHOD, which claims the benefit of Ser. No. 60/619,308 filed on Oct. 15, 2004; and claims the benefit of Ser. No. 60/632,147 filed on Dec. 1, 2004; and claims the benefit of Ser. No. 60/636,845 filed on Dec. 15, 2004; and claims the benefit of Ser. No. 60/711,310 filed on Aug. 25, 2005, the disclosures of which are incorporated herein in their entirety.

US Referenced Citations (217)
Number Name Date Kind
4403604 Wilkinson et al. Sep 1983 A
4607618 Angelchik Aug 1986 A
5234454 Bangs Aug 1993 A
5306300 Berry Apr 1994 A
5366504 Andersen et al. Nov 1994 A
5507755 Gresl et al. Apr 1996 A
5662713 Andersen et al. Sep 1997 A
5741279 Gordon et al. Apr 1998 A
5820584 Crabb Oct 1998 A
6146416 Andersen et al. Nov 2000 A
6264700 Kilcoyne et al. Jul 2001 B1
6280415 Johnson Aug 2001 B1
6312437 Kortenbach Nov 2001 B1
6355070 Andersen et al. Mar 2002 B1
6398802 Yee Jun 2002 B1
6432040 Meah Aug 2002 B1
6447533 Adams Sep 2002 B1
6468298 Pelton Oct 2002 B1
6544291 Taylor Apr 2003 B2
6558400 Deem et al. May 2003 B2
6572627 Gabbay Jun 2003 B2
6656194 Gannoe et al. Dec 2003 B1
6675809 Stack et al. Jan 2004 B2
6736828 Adams et al. May 2004 B1
6740121 Geitz May 2004 B2
6746460 Gannoe et al. Jun 2004 B2
6755869 Geitz Jun 2004 B2
6773440 Gannoe et al. Aug 2004 B2
6800081 Parodi Oct 2004 B2
6802868 Silverman et al. Oct 2004 B2
6845776 Stack et al. Jan 2005 B2
6916332 Adams Jul 2005 B2
6960233 Berg et al. Nov 2005 B1
6981978 Gannoe Jan 2006 B2
6994095 Burnett Feb 2006 B2
6994715 Gannoe et al. Feb 2006 B2
7025791 Levine et al. Apr 2006 B2
7033373 de la Torre et al. Apr 2006 B2
7033384 Gannoe et al. Apr 2006 B2
7037344 Kagan et al. May 2006 B2
7044979 Silverman et al. May 2006 B2
7066945 Hashiba et al. Jun 2006 B2
7083629 Weller et al. Aug 2006 B2
7083630 DeVries et al. Aug 2006 B2
7087088 Berg et al. Aug 2006 B2
7097650 Weller et al. Aug 2006 B2
7097665 Stack et al. Aug 2006 B2
7111627 Stack et al. Sep 2006 B2
7146984 Stack et al. Dec 2006 B2
7152607 Stack et al. Dec 2006 B2
7167750 Knudson et al. Jan 2007 B2
7211114 Bessler et et al. May 2007 B2
7220284 Kagan et al. May 2007 B2
7232461 Ramer Jun 2007 B2
7347875 Levine et al. Mar 2008 B2
7431725 Stack et al. Oct 2008 B2
7445010 Kugler et al. Nov 2008 B2
7449024 Stafford Nov 2008 B2
7678068 Levine et al. Mar 2010 B2
7682330 Meade et al. Mar 2010 B2
7704264 Ewers et al. Apr 2010 B2
7708752 Durgin May 2010 B2
7753870 Demarais et al. Jul 2010 B2
7771382 Levine et al. Aug 2010 B2
7794447 Dann et al. Sep 2010 B2
7815589 Meade et al. Oct 2010 B2
7815591 Levine et al. Oct 2010 B2
7846174 Baker Dec 2010 B2
7922650 McWeeney et al. Apr 2011 B2
7976488 Levine et al. Jul 2011 B2
7981163 Meade et al. Jul 2011 B2
8029455 Stack et al. Oct 2011 B2
8043355 Shin et al. Oct 2011 B2
8100931 Baker et al. Jan 2012 B2
8137301 Levine et al. Mar 2012 B2
8142513 Shalon et al. Mar 2012 B2
8162871 Levine et al. Apr 2012 B2
8252009 Weller Aug 2012 B2
8282598 Belhe et al. Oct 2012 B2
8372087 Baker et al. Feb 2013 B2
8447403 Sharma et al. May 2013 B2
8506477 Waller et al. Aug 2013 B2
8529431 Baker et al. Sep 2013 B2
8556956 Cully et al. Oct 2013 B2
8672831 Baker et al. Mar 2014 B2
8721528 Ho et al. May 2014 B2
8778011 Ryan Jul 2014 B2
8784436 Ho et al. Jul 2014 B2
8801599 Baker et al. Aug 2014 B2
8894670 Baker et al. Nov 2014 B2
9055998 Baker Jun 2015 B2
9060844 Kagan et al. Jun 2015 B2
9107742 Cully et al. Aug 2015 B2
9198789 Baker et al. Dec 2015 B2
9375338 Baker et al. Jun 2016 B2
9414948 Baker et al. Aug 2016 B2
9545326 Baker et al. Jan 2017 B2
9549833 McHugo Jan 2017 B2
9629733 Roeder Apr 2017 B2
9839545 Baker et al. Dec 2017 B2
9872787 Baker et al. Jan 2018 B2
10182901 Baker et al. Jan 2019 B2
10271940 Baker et al. Apr 2019 B2
20010011543 Forsell Aug 2001 A1
20010020189 Taylor Sep 2001 A1
20020032487 Dua et al. Mar 2002 A1
20020091395 Gabbay Jul 2002 A1
20030040804 Stack et al. Feb 2003 A1
20030040808 Stack et al. Feb 2003 A1
20030065359 Weller et al. Apr 2003 A1
20030109935 Geitz Jun 2003 A1
20030199989 Stack et al. Oct 2003 A1
20030212450 Schlick Nov 2003 A1
20040044357 Gannoe et al. Mar 2004 A1
20040087976 DeVries et al. May 2004 A1
20040092892 Kagan et al. May 2004 A1
20040106987 Palasis et al. Jun 2004 A1
20040116999 Ledergerber Jun 2004 A1
20040117031 Stack et al. Jun 2004 A1
20040122456 Vahid Jun 2004 A1
20040138761 Stack et al. Jul 2004 A1
20040143342 Stack et al. Jul 2004 A1
20040148034 Kagan et al. Jul 2004 A1
20040172141 Stack et al. Sep 2004 A1
20040210111 Okada Oct 2004 A1
20040220682 Levine et al. Nov 2004 A1
20050004582 Edoga et al. Jan 2005 A1
20050043683 Ravo Feb 2005 A1
20050080395 Levine et al. Apr 2005 A1
20050096728 Ramer May 2005 A1
20050125020 Meade et al. Jun 2005 A1
20050177181 Kagan Aug 2005 A1
20050192599 Demarais Sep 2005 A1
20050192629 Saadat et al. Sep 2005 A1
20050197715 Kugler et al. Sep 2005 A1
20050228504 Demarais Oct 2005 A1
20050245788 Gerber Nov 2005 A1
20050245957 Starkebaum et al. Nov 2005 A1
20050247320 Stack et al. Nov 2005 A1
20050251165 Vaughan et al. Nov 2005 A1
20050251176 Swanstrom et al. Nov 2005 A1
20050283235 Kugler et al. Dec 2005 A1
20060020277 Gostout et al. Jan 2006 A1
20060036293 Whitehurst et al. Feb 2006 A1
20060064120 Levine et al. Mar 2006 A1
20060074473 Gertner Apr 2006 A1
20060089571 Gertner Apr 2006 A1
20060142844 Lowe et al. Jun 2006 A1
20060149307 Durgin Jul 2006 A1
20060155375 Kagan et al. Jul 2006 A1
20060161139 Levine et al. Jul 2006 A1
20060190019 Gannoe et al. Aug 2006 A1
20060247721 Maschino et al. Nov 2006 A1
20060253131 Wolniewicz, III Nov 2006 A1
20060253142 Bjerken Nov 2006 A1
20060253191 Salahieh et al. Nov 2006 A1
20060264699 Gertner Nov 2006 A1
20060265082 Meade et al. Nov 2006 A1
20070005147 Levine et al. Jan 2007 A1
20070010866 Dann et al. Jan 2007 A1
20070010875 Trout et al. Jan 2007 A1
20070088428 Teichman Apr 2007 A1
20070112409 Wu et al. May 2007 A1
20070123994 Ortiz et al. May 2007 A1
20070166396 Badylak et al. Jul 2007 A1
20070179590 Lu et al. Aug 2007 A1
20070198035 Threlkeld Aug 2007 A1
20070208429 Leahy Sep 2007 A1
20070233221 Raju Oct 2007 A1
20070260112 Rahmani Nov 2007 A1
20070270742 Guetty Nov 2007 A1
20070276432 Stack et al. Nov 2007 A1
20070293716 Baker et al. Dec 2007 A1
20080015523 Baker Jan 2008 A1
20080015618 Sonnenschein et al. Jan 2008 A1
20080015633 Abbott et al. Jan 2008 A1
20080065122 Stack et al. Mar 2008 A1
20080065136 Young Mar 2008 A1
20080215076 Baker Sep 2008 A1
20080312678 Pasricha Dec 2008 A1
20090018389 Laufer et al. Jan 2009 A1
20090138071 Cheng et al. May 2009 A1
20090177215 Stack et al. Jul 2009 A1
20090187230 Dilorenzo Jul 2009 A1
20090240340 Levine et al. Sep 2009 A1
20090248171 Levine et al. Oct 2009 A1
20090270818 Duke Oct 2009 A1
20100010298 Bakos et al. Jan 2010 A1
20100030017 Baker et al. Feb 2010 A1
20100114124 Kelleher et al. May 2010 A1
20100114130 Meade et al. May 2010 A1
20100256775 Belhe et al. Oct 2010 A1
20100280313 Gasche et al. Nov 2010 A1
20100305590 Holmes et al. Dec 2010 A1
20110004146 Priplata et al. Jan 2011 A1
20110009690 Belhe et al. Jan 2011 A1
20110264234 Baker et al. Oct 2011 A1
20120053653 Hiernaux et al. Mar 2012 A1
20120083871 Ryan Apr 2012 A1
20120095497 Babkes et al. Apr 2012 A1
20120191213 Baker et al. Jul 2012 A1
20120191215 Baker et al. Jul 2012 A1
20120203061 Birk Aug 2012 A1
20130123811 Baker et al. May 2013 A1
20130296913 Foote et al. Nov 2013 A1
20130310327 Sambursky et al. Nov 2013 A1
20130324902 Miller et al. Dec 2013 A1
20140135799 Henderson May 2014 A1
20140158747 Measamer et al. Jun 2014 A1
20140277341 Havel et al. Sep 2014 A1
20150039092 Baker et al. Feb 2015 A1
20150182239 Baker et al. Jul 2015 A1
20160151233 Baker et al. Jun 2016 A1
20160228268 Hingston et al. Aug 2016 A1
20170172723 Foote et al. Jun 2017 A1
20180104080 Baker et al. Apr 2018 A1
20190298560 Belhe et al. Oct 2019 A1
Foreign Referenced Citations (45)
Number Date Country
108938163 Dec 2018 CN
0760696 Aug 2001 EP
1808888 Jul 2007 EP
2240215 Jan 2014 EP
2660101 Jun 1997 JP
2006-103873 Apr 2006 JP
2007508053 Apr 2007 JP
2011509758 Mar 2011 JP
2045233 Oct 1995 RU
94026119 Aug 1996 RU
2386455 Apr 2010 RU
WO 9322986 Nov 1993 WO
WO 9412136 Jun 1994 WO
WO 0135834 May 2001 WO
WO 0185034 Nov 2001 WO
WO 02060328 Aug 2002 WO
WO 02094105 Nov 2002 WO
WO 2004019826 Mar 2004 WO
WO 2004064680 Aug 2004 WO
WO 2004064685 Aug 2004 WO
WO 2005037152 Apr 2005 WO
WO 2006044640 Apr 2006 WO
WO 2006078672 Jul 2006 WO
WO 2007092390 Aug 2007 WO
WO 2008100984 Aug 2008 WO
WO 2008101048 Aug 2008 WO
WO 2008101078 Aug 2008 WO
WO 2009048398 Apr 2009 WO
WO 2009091899 Jul 2009 WO
WO 2010117641 Oct 2010 WO
WO 2011056608 May 2011 WO
WO 2011063307 May 2011 WO
WO 2011089601 Jul 2011 WO
WO 2011097209 Aug 2011 WO
WO 2011116025 Sep 2011 WO
WO 2012044917 Apr 2012 WO
WO 2012136249 Oct 2012 WO
WO 2012162114 Nov 2012 WO
WO 2013090190 Jun 2013 WO
WO 2013134227 Sep 2013 WO
WO 2014141239 Sep 2014 WO
WO 2015031077 Mar 2015 WO
WO 2016109346 Jul 2016 WO
WO 2018073752 Apr 2018 WO
WO 2018083632 May 2018 WO
Non-Patent Literature Citations (19)
Entry
International Search Report of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/US12/38480, dated Jul. 30, 2012.
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/US12/38480, dated Nov. 29, 2013.
“Obesity: Super-Sized Medical Device Market”, Start-Up, Mar. 2003, Technology Strategies (Long Article), pp. 1-10 and a cover page.
Andrew S. Lowe, M.D. and Maria B. Sheridan, M.D., “Esphogeal Stenting”, Seminars in Interventional Radiology, vol. 21, No. 3, 2004, pp. 157-166.
“Polyflex® Espohageal Stent”, Silicone Covered Stent, Boston Scientific, three pages (2003).
Andrew F.R. Dixon, Johgn B. Dixon, and Paul E. O'Brien, “Laparoscopic Adjustable Gastric Banding Induces Prolonged Satiety: A Randomized Blind Crossover Study”, The Journal of Clinical Endocrinology & Metabolism , pp. 813-819, 2005.
Roman, S. et al., “Intragastric balloon for ‘non-morbid’ obesity: a retrospective evaluation of tolerance and efficacy,” Obes. Surg., 2004, 14(4), 539-44, abstract, [on-line], [found Apr. 17, 2009, from Pubmed database].
Busetto, L. et al., “Preoperative weight loss by intragastric balloon in super-obese patients treated with laparoscopic gastric banding: a case-control study,” Obes Surg., 2004, 14(5), 671-6, abstract, [on-line], [found Apr. 17, 2009, from Pubmed database].
Summary of Official Action dated Oct. 29, 2009, from the Israel Patent Office in a patent application corresponding to the present application.
Lowe, Andrew S., M.D. and Sheridan, Maria B., M.D., “Esophageal Stenting,” annotated by Israel Patent Office (2004).
Abstract and claims of U.S. Pat. No. 6,960,233 annotated by the Israel Patent Office (Nov. 1, 2005).
Schembre, Drew, “Advances in Esophageal Stenting: the Evolution of Fully Covered Stents for Malignant and Benign Disease,” Adv. Ther., Springer Healthcare, Apr. 1, 2010, pp. 1-13.
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/US08/53912, completed Aug. 19, 2009.
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/US05/36991, completed Mar. 6, 2006.
S. Fukudo, T. Nomura, M. Hongo, “Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowl syndrome”, Jan. 19, 1998.
D.G. Maxton, D.F. Martin, P.J. Whorwell, M. Godfrey. “Abdominal distension in female patients with irritable bowel syndrome: exploration of possible mechanisms”, Aug. 3, 1990.
Dixon et al. “Health Outcomes of Severely Obese Type 2 Diabetic Subjects 1 Year After Laparoscopic Adjustable Gastric Banding”. 2002. Diabetic Care 25:358-363. (Year 2002).
International Search Report of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/IB2017/056838, dated Mar. 7, 2018.
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/IB2017/056838, dated May 7, 2019.
Related Publications (1)
Number Date Country
20200390579 A1 Dec 2020 US
Provisional Applications (4)
Number Date Country
60711310 Aug 2005 US
60636845 Dec 2004 US
60632147 Dec 2004 US
60619308 Oct 2004 US
Continuations (8)
Number Date Country
Parent 15805495 Nov 2017 US
Child 17004591 US
Parent 15211034 Jul 2016 US
Child 15805495 US
Parent 14920403 Oct 2015 US
Child 15211034 US
Parent 14314444 Jun 2014 US
Child 14920403 US
Parent 14142131 Dec 2013 US
Child 14314444 US
Parent 13331425 Dec 2011 US
Child 14142131 US
Parent 12915952 Oct 2010 US
Child 13331425 US
Parent 11463192 Aug 2006 US
Child 12915952 US
Continuation in Parts (1)
Number Date Country
Parent PCT/US2005/036991 Oct 2005 US
Child 11463192 US